Achieving a high cure rate with direct-acting antivirals for chronic Hepatitis C virus infection in Cameroon: a multi-clinic demonstration project

Liza Coyer, Oudou Njoya, Richard Njouom, Tatiana Mossus, Mathurin Pierre Kowo, Frida Essomba, Alexander Boers, Roel Coutinho, Pascale Ondoa, Catherine Bilong, Isabelle Dang Babagnak, Dyane Kamto, Paul Talla, Eric Tchoumi

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)


Objectives: Highly effective direct-acting antivirals (DAAs) for Hepatitis C treatment are largely inaccessible in sub-Saharan Africa. Data on treatment feasibility and outcomes in clinical settings are limited. We assessed the feasibility of achieving a high (≥90%) cure rate with DAAs in six gastroenterology clinics in Cameroon. Methods: Patients with chronic Hepatitis C virus (HCV) infection were treated for 12 or 24 weeks with ledipasvir/sofosbuvir, ledipasvir/sofosbuvir/ribavirin or sofosbuvir/ribavirin, depending on the stage of liver disease and HCV genotype. The cure rate was defined as the proportion of patients with a sustained virological response 12 weeks after treatment completion (SVR12) among all treatment completers. Results: We identified 190 HCV RNA positive patients between September-2017 and August-2018, 161 (84.7%) of whom started treatment. 105 (65.2%) were female, median age was 61.3 years [IQR = 55.9–66.9] and 11 (6.8%) were HIV-positive. Median plasma HCV RNA was 6.0 log10IU/mL [IQR = 5.6–6.4]. HCV genotypes identified were 1 (34.8%), 2 (13.7%), 4 (50.9%), 1 and 4 (0.6%); 46 (28.6%) strains of 160 single-genotype infections were non-subtypeable. Of 158 treatment completers, 152 (96.2%, 95%CI = 91.9–98.6%) achieved SVR12. Six patients did not achieve SVR12: five carried HCV with NS5A resistance mutations and one with NS5B resistance mutations. Three patients died before and two after treatment completion. The most common adverse events were asthenia (12.0%), headache (11.4%) and dizziness (18.9%). Conclusion: High cure rates of Hepatitis C with DAAs are achievable in clinical settings of Cameroon. However, the accessibility and provision of HCV screening, diagnosis, treatment, monitoring and care should be addressed for large-scale implementation.
Original languageEnglish
Pages (from-to)1098-1109
Number of pages12
JournalTropical Medicine & International Health
Issue number9
Early online date2020
Publication statusPublished - 1 Sep 2020


  • Africa
  • Cameroon
  • Hepatitis C virus (HCV)
  • cure rate
  • direct-acting antiviral

Cite this